Tiger Brokers

Zhongzhi Pharmaceutical FY2025 profit attributable to equity holders drops 81.8% to RMB17 million; revenue falls 21.6% to RMB1.7 billion

Reuters
Yesterday
Zhongzhi Pharmaceutical FY2025 profit attributable to equity holders drops 81.8% to RMB17 million; revenue falls 21.6% to RMB1.7 billion
  • Zhongzhi Pharmaceutical published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB1.7 billion, down 21.6%.
  • Gross profit was RMB945.9 million, down 26.6%, and gross margin was 54.4%, down 3.8 percentage points.
  • Profit attributable to owners of the parent was RMB17.3 million, down 81.8%, while basic and diluted earnings per share were RMB0.02, down 81.8%.
  • Pharmaceutical manufacturing revenue was RMB1.2 billion, down 25.6% due to a longer inventory consumption period amid weaker market consumption power and tightened market policies.
  • Chain pharmacies revenue was RMB528.8 million, down 10.4% as competition weighed on footfall, and the company proposed no final dividend (vs. a prior final dividend of HKD0.05 per share).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhongzhi Pharmaceutical Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12070040), on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10